Aug 18, 2026 08:11AM
Aug 18, 2026 02:52AM
Aug 17, 2026 12:07PM
Aug 17, 2026 07:01AM
Aug 17, 2026 07:00AM
Aug 14, 2026 04:32PM
Aug 5, 2026 07:00AM EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Jul 30, 2026 07:01AM
Jul 30, 2026 07:00AM
Jul 16, 2026 07:00AM
Jul 13, 2026 07:00AM
Jun 16, 2026 07:00AM
May 19, 2026 07:00AM
May 18, 2026 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 14, 2026 07:01AM
May 14, 2026 07:00AM
May 6, 2026 07:00AM
Apr 29, 2026 07:00AM
Apr 16, 2026 04:01PM
Mar 16, 2026 07:00AM
Mar 4, 2026 07:00AM EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
Mar 2, 2026 07:00AM
Mar 2, 2026 07:00AM
Feb 25, 2026 07:00AM
Feb 24, 2026 07:00AM
Feb 18, 2026 07:00AM
Feb 18, 2026 07:00AM
Feb 17, 2026 07:00AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 5, 2026 07:00AM
Jan 16, 2026 07:00AM
Jan 7, 2026 09:02AM
Jan 7, 2026 07:03AM
Jan 7, 2026 07:00AM
Dec 21, 2025 08:00PM
Dec 17, 2025 07:00AM EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
Dec 16, 2025 07:00AM
Dec 9, 2025 10:49AM
Nov 19, 2025 07:00AM
Nov 19, 2025 07:00AM
Nov 17, 2025 07:00AM
Nov 5, 2025 07:00AM
Nov 3, 2025 07:00AM EyePoint Announces Participation at Upcoming Investor Conferences
Oct 29, 2025 07:00AM
Oct 16, 2025 07:00AM
Oct 14, 2025 10:43PM
Oct 14, 2025 10:43PM
Oct 14, 2025 04:35PM
Oct 14, 2025 04:35PM
Oct 14, 2025 04:01PM EyePoint initiates Phase 3 trials for DURAVYU in diabetic macular edema
Oct 14, 2025 04:01PM

330,215 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All